The Leiden University Medical Center (LUMC) and Ixaka Ltd. have announced a research collaboration on 30 March 2021, to better understand REX-001, Ixaka’s lead cell therapy product. The project will be led by Professor Paul Quax, Head of Experimental Vascular Surgery at the LUMC, to support accelerated development of REX-001 in Phase III clinical trials for the treatment of chronic limb-threatening ischemia (CLTI).
CLTI is a life-threatening vascular disease caused by a build-up of fatty deposits in the arteries, which limits the adequate flow of blood and oxygen to a specific part of the body, such as the leg muscles. According to Quax: “there are not many available options to treat the disease as it progresses and the current procedures to manage symptoms of CLTI at advanced stages are often unsuitable or ineffective”. For example, cutting-edge methods such as the use of minimally-invasive catheters and surgical reconstruction do not help in restoring blood flow or preventing major amputations. “This has created a critical need for new and innovative therapies”, highlights Quax.
Long have we awaited the moment that we could welcome international students at the LUMC again. Due to COVID, all student mobility was cancelled for over 1,5 years. And despite still having regulations in place, especially during the first semester of the academic year 2021-2022, it was refreshing to cautiously welcome international students again. We’re so pleased to see that the students who came to Leiden had a fun, meaningful and above all, educational experience. In a questionnaire, they’ve given us an insight into how they experienced student mobility during these strange times.
Twice a year, the Research Mobility Fellowships of the European Joint Programme on Rare Diseases (EJP RD) from the European Reference Networks (ERN) get awarded to prominent researchers or MDs to develop new skills and expertise in a European institution specialized in research on rare diseases.
On May 30th, international experts and politicians gathered in Leiden to discuss global health issues during the Global Impact in Health Symposium. Lively discussions were held on matters concerning equal worldwide access to vaccines and diversity within clinical research. New scientific insights were also shared, including on vaccine response differences between African and European populations. Missed the event? Check out the after movie and get in touch!